LogicBio Therapeutics (LogicBio Therapeutics) Goodwill : $0.00 Mil (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is LogicBio Therapeutics Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. LogicBio Therapeutics's goodwill for the quarter that ended in Jun. 2022 was $0.00 Mil.

LogicBio Therapeutics Goodwill Historical Data

The historical data trend for LogicBio Therapeutics's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LogicBio Therapeutics Goodwill Chart

LogicBio Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Goodwill

Get a 7-Day Free Trial

LogicBio Therapeutics Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Goodwill	Get a 7-Day Free Trial															-	-	-	-	-

LogicBio Therapeutics Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.

LogicBio Therapeutics (NAS:LOGC) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

LogicBio Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Goodwill-to-Asset (A: Dec. 2021 )	=	Goodwill	/	Total Assets
	=	0	/	62.77
	=	0.00

LogicBio Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Jun. 2022 is calculated as

Goodwill-to-Asset (Q: Jun. 2022 )	=	Goodwill	/	Total Assets
	=	0	/	47.017
	=	0.00

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.

LogicBio Therapeutics Goodwill Related Terms

Thank you for viewing the detailed overview of LogicBio Therapeutics's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.

LogicBio Therapeutics (LogicBio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LogicBio Therapeutics Inc (NAS:LOGC) » Definitions » Goodwill

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, 2nd Floor, Lexington, MA, USA, 02421

Website

https://www.logicbio.com

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.

Executives

Mark J Enyedy	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Mariana Nacht	officer: Chief Scientific Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Daniel Gruskin	officer: Chief Medical Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Susan Kahn	director	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Joshua Blacher	officer: Interim CFO	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Andrea Paul	officer: General Counsel and Secretary	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Frederic Chereau	director, officer: See Remarks	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Kyle Chiang	officer: Chief Operating Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jonathan Quick	officer: Senior Director-Finance	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jeff Goater	director	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Erez Chimovits	director	P.O. BOX 4023, HERZLIYA PITUACH L3 4614001
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022